Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

Cerebrospinal Fluid Leak Clinical Trial

Official title:

A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated FS VH S/D 500 S-apr (Tisseel) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02891070
• Other study ID #: 3599-001
• Secondary ID: 2015-005535-40
• Status: Completed
• Phase: Phase 3
• Start date: October 11, 2016
• Est. completion date: August 22, 2018

Study information

• Verified date: August 2019
• Source: Baxter Healthcare Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 224
• Est. completion date: August 22, 2018
• Est. primary completion date: August 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients undergoing craniotomy/craniectomy for pathological processes in the PF or ST region

2. Patients must be willing and able to participate in the study and provide written IC before any protocol specific assessment is performed

3. Patients must be willing to receive peri-operative antibiotic prophylaxis

4. Female patients of childbearing potential must present with a negative serum pregnancy test, and must agree to employ adequate birth control measures [restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products] for the duration of their participation in the study

5. Patients are willing and able to comply with the requirements of the protocol

Exclusion Criteria:

1. Patients with a dural lesion from a recent surgery that still has the potential for CSF leakage

2. Patients who had undergone chemotherapy treatment, excluding hormonal therapy, within 3 weeks prior to the planned procedure, or with chemotherapy scheduled within 7 days following surgery

3. Patients with radiation therapy to the surgical site or standard fractionated radiation therapy scheduled within 7 days following surgery

4. Patients with a previous craniotomy/craniectomy within 6 months prior to the study surgery

5. Use of corticosteroids on a chronic basis (defined as daily use of corticosteroids for =8 weeks) for purposes other than decreasing the symptoms of systemic chemotherapy (unless if those steroids were discontinued 4 weeks prior to the planned surgery)

6. Patients with a known hypersensitivity to the components of the IP or control (human fibrinogen, synthetic aprotinin, human albumin, human FXIII, tri sodium citrate, histidine, niacinamide, polysorbate 80, human thrombin, polyethylene glycol [PEG], trilysine amine)

7. Patients with a known hypersensitivity to US Federal Drug & Cosmetic Blue #1 dye

8. Evidence of an infection indicated by any one of the following: clinical examination supporting the diagnosis of infection, fever (temperature >100.7°F or 38.2°C), positive urine culture, positive blood culture, positive chest X ray consistent with pulmonary infection, or infection along the planned surgical path. A white blood cell (WBC) count of <20000 cells/µL is permitted if the patient is being treated with steroids in the absence of all other infection parameters

9. Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period

10. Female patients who are nursing

11. Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrolment or anticipated in the 60-day Follow-up period

12. Patients with severely altered renal function as confirmed by local laboratory reference ranges for serum creatinine and/or hepatic function (alanine aminotransferase [ALT], aspartate aminotransferase >3 × upper limit of normal [ULN])

13. Patients who currently have or have had a compromised immune system (such as Acquired Immune Deficiency Syndrome [AIDS]) or autoimmune disease, or were on chronic immunosuppressant agents

14. Patients with uncontrolled diabetes as evidenced by the institution's standard of care (glycated haemoglobin [HbA1c] >7%, blood glucose, etc.)

15. Patients with traumatic injuries to the head

16. Patients with dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff

17. Patients requiring surgical approaches that would not allow sutured dural closure such as trans-sphenoidal or translabyrinthine/-petrosal/-mastoid. Superficial penetration of mastoid air cells is allowed

18. Patients with hydrocephalus, except occlusive hydrocephalus caused by PF pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure

19. Existing CSF (ventricular, etc.) drains, Cushing/Dandy cannulation, or Burr holes which damage the dura

20. Patients with confined bony structures where nerves are present and neural compression may result due to swelling

Related Conditions & MeSH terms

• Cerebrospinal Fluid Leak

Intervention

Drug:
• FS VH S/D 500 s-apr

Device:
• DuraSeal Dural Sealant

Locations

Country	Name	City	State
Czechia	St. Anne's University Hospital Brno	Brno
Czechia	University Hospital Brno	Brno
Czechia	University Hospital Hradec Kralove	Hradec Kralove
Czechia	University Hospital Ostrava	Ostrava
Czechia	Hospital Na Homolce	Praha 5
Czechia	University Hospital Motol	Praha 5 - Motol
Germany	University Hospital Leipzig	Leipzig
Germany	Hospital Bogenhausen Municipal Hospital	Munich
Germany	University Hospital Rostock	Rostock
Spain	University Hospital Germans Trias I Pujol	Badalona
Spain	Hospital Clinic I Provincial de Barcelona	Barcelona
Spain	University Hospital 12 de Octubre	Madrid
Spain	University Hospital Foundation Jimenez Diaz	Madrid
Spain	University Hospital Son Espases	Palma de Mallorca
Spain	University General Hospital of Valencia	Valencia
United States	University of Virginia School of Medicine	Charlottesville	Virginia
United States	University Hospitals Case Medical Center	Cleveland	Ohio
United States	The Ohio State University	Columbus	Ohio
United States	Henry Ford Hospital	Detroit	Michigan
United States	Houston Methodist Neurological Institute	Houston	Texas
United States	University of Minnesota	Minneapolis	Minnesota
United States	Temple University School of Medicine	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Baystate Medical Center	Springfield	Massachusetts
United States	Southern Illinois University School of Medicine	Springfield	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Baxter Healthcare Corporation

Countries where clinical trial is conducted

United States,  Czechia,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With No CSF Leak During and After Surgery	Participants who have no intra-operative CSF leak from dural repair after up to two applications during Valsalva maneuver (25 cm H2O for up to 5 - 10 seconds), or post-operative CSF leak within 30 (+3) days post-operatively. The Valsalva maneuver was performed by the anaesthesiologist to increase the intra-thoracic pressure (e.g., by increasing the positive end-expiratory pressure or by giving a large tidal volume and holding the inflating pressure) to approximately 25 cm H2O, constantly for up to 5 - 10 seconds to transiently elevate the intracranial pressure and test for any CSF leaks. The suture line was to be watertight after up to two product/control applications and Valsalva maneuvers.	Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
Secondary	Number of Participants With no Intra-operative CSF Leaks Following Final Valsalva Maneuver	Assessment of whether the suture line was not watertight causing CSF leaks after up to two product/control applications and Valsalva maneuvers.	Day 0 (Intra-operative)
Secondary	Number of Participants With CSF Leaks Within 30 (+3) Days Post-operatively	Cerebrospinal fluid leak was defined as any overt flow, seepage, weeping, or sweating of CSF through the dura suture line, regardless of volume. All post-operative CSF leaks were primarily diagnosed based on a detailed history and physical examination, including neurological examination. Although not standard of care post-operatively, imaging tests such as computed tomography/magnetic resonance imaging (MRI) were considered if there was a high clinical suspicion of a CSF leak.	Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative
Secondary	Duration in Surgery (Minutes)	Patients undergoing elective cranial surgery for the treatment of a pathological condition (e.g., benign/malignant tumours, vascular malformations, or Chiari type 1 malformations) specifically located in the posterior fossa (PF) or supratentorial (ST) regions.	Day 0 (intra-operatively)
Secondary	Time From Dural Closure (Application of IP) Until End of Surgery	Suture closure techniques include continuous simple, continuous locked, interrupted.	Day 0 (Intra-operatively)
Secondary	Length of Stay in Hospital (Days).	Days in hospital calculation is Day 0 - Discharge.	Day 0 to Day 60 (Study Completion)